Table 1.

Participant demographics, cancer characteristics, and treatment at most recent follow-up

Characteristic (N = 52)		Frequency
Age at diagnosis (years), median (IQR)		54.5 (43, 65.5)
Current age, median (IQR)		59 (47, 71.5)
Race	Caucasian	71%
	African American	27%
	Other	2%
Ethnicity	Hispanic	2%
	Non-Hispanic	98%
Education	Less than high school	4%
	High school/GED	17%
	Vocational and Associates	21%
	Undergraduate degree BA/BS	25%
	Graduate degree MS/MBA/JD/PhD/MD	33%
Insurance status	Private	73%
	Medicare	27%
Marital status*	Single	12%
	Married/Partnered	61%
	Separated/Divorced	17%
	Widowed	10%
Menopausal at diagnosis	Yes	62%
	No	38%
Mutation present in those with genetic testing (n = 25)	BRCA1 (n = 4)	16%
	BRCA2 (n = 1)	4%
	PALB2 (n = 1)	4%
Stage	1	31%
	2	52%
	3	17%
Node status	Positive	54%
	Negative	46%
Hormone receptor status	Positive	56%
	Negative	44%
HER-2 receptor status	Positive	42%
	Negative	58%
Surgery	Lumpectomy	44%
	Bilateral mastectomy	31%
	Bilateral nipple sparing mastectomy	8%
	Bilateral skin-sparing mastectomy	6%
	UL mastectomy	11%
Lymph node assessment	Sentinel lymph node (SLN) biopsy	73%
	Axillary lymph node dissection (ALND)	19%
Chemotherapy	Yes	94%
	No	6%
Endocrine therapy	Overall	56%
	Among HR-positive	97%
	Tamoxifen	31%
	Aromatase inhibitor 20	69%
Anti-HER2 therapy	Yes	42%
	No	58%
Radiation	Breast	56%
	Chest	44%
	Boost	18%
	LN	59%
Time from diagnosis to SV (years), median (IQR)		0.9 (0.7, 1.3)
Time from diagnosis to most recent follow-up (years), median (IQR)		3.1 (2.4, 4.2)
Time from SV to most recent follow-up (years), median (IQR)		1.9 (1.5, 3.1)

^*At SV, 13% were single, 66% were married/partnered, 9% were separated/divorced, and 11% were widowed